Cover Image

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine

Abstract Rivaroxaban (RIV; Xarelto; Janssen Pharmaceuticals, Beerse, Belgium) is one of the direct oral anticoagulants. The drug is a strong substrate of cytochrome P450 (CYP) enzymes and efflux transporters. This study aimed to develop a physiologically‐based pharmacokinetic (PBPK) model for RIV. I...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lien Thi Ngo (Author), Sung‐yoon Yang (Author), Sooyoung Shin (Author), Duc Tuan Cao (Author), Hung Van Nguyen (Author), Sangkeun Jung (Author), Jae‐Young Lee (Author), Jong‐Hwa Lee (Author), Hwi‐yeol Yun (Author), Jung‐woo Chae (Author)
Format:	Book
Published:	Wiley, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug-Drug Interaction between Rivaroxaban and Carbamazepine in Humans
by: Lien Thi Ngo, et al.
Published: (2023)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020)

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators
by: Lien Thi Ngo, et al.
Published: (2023)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
by: Stefan Willmann, et al.
Published: (2021)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
by: Jia Chong, et al.
Published: (2020)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Minsoo Kim, et al.
Published: (2019)

Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models
by: Hyo-jeong Ryu, et al.
Published: (2021)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
by: Xiao-Qin Liu, et al.
Published: (2023)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost C, et al.
Published: (2014)

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
by: Rui-juan Xu, et al.
Published: (2021)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023)

Fine-tuning of BERT Model to Accurately Predict Drug-Target Interactions
by: Hyeunseok Kang, et al.
Published: (2022)

Fractal Kinetic Implementation in Population Pharmacokinetic Modeling
by: Woojin Jung, et al.
Published: (2023)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
by: Alexander Solms, et al.
Published: (2019)

Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs
by: Yuanyuan Meng, et al.
Published: (2022)

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
by: Huamin Ding, et al.
Published: (2024)

Drug approval processes: A case study of rivaroxaban
by: Sally A Arif, et al.
Published: (2013)

Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023)

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
by: Robert Hoerr, et al.
Published: (2022)

The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers
by: Jong-Hwa Lee, et al.
Published: (2021)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
by: Michael Becka, et al.
Published: (2012)

Clinical Evaluation of Acetaminophen-Galgeuntang Interaction Based on Population Approaches
by: Quyen Thi Tran, et al.
Published: (2020)

Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data
by: Won-ho Kang, et al.
Published: (2021)

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis
by: Quyen Thi Tran, et al.
Published: (2022)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
by: Noppaket Singkham, et al.
Published: (2022)

Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side
by: Jean Terrier, et al.
Published: (2023)

Absorption Distribution Metabolism Excretion and Toxicity Property Prediction Utilizing a Pre-Trained Natural Language Processing Model and Its Applications in Early-Stage Drug Development
by: Woojin Jung, et al.
Published: (2024)

Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor‐Mediated Recycling of HL2351, a Novel Hybrid Fc‐Fused Interleukin‐1 Receptor Antagonist, to Optimize Dosage Regimen
by: Lien Ngo, et al.
Published: (2020)

Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling
by: Taeheon Kim, et al.
Published: (2024)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
by: Yoo-Kyung Song, et al.
Published: (2021)

A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption
by: Hyun-moon Back, et al.
Published: (2018)

Spontaneous Subcapsular Hematoma from Rivaroxaban
by: Swetha Chenna, et al.
Published: (2018)

Intravesicular Onabotulinumtoxin A Hemorrhage on Rivaroxaban
by: Allison Eubanks, et al.
Published: (2019)

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019)

Demeanor of rivaroxaban in activated/inactivated FXa
by: Kaname Seki, et al.
Published: (2017)

Hemomediastino en tomador de rivaroxaban
by: Pablo Ruiz-Sada, et al.
Published: (2016)

Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes
by: Xu Wang, et al.
Published: (2022)